Skip to content
Medical Health Aged Care, Science

New study finds constipation is a significant risk factor for major cardiac events

Monash University 2 mins read

An international study led by Monash University researchers has found a surprising connection between constipation and an increased risk of major adverse cardiac events (MACE), including heart attacks, strokes and heart failure.

The study, led by Professor Francine Marques from the School of Biological Sciences and published in the American Journal of Physiology-Heart and Circulatory Physiology analysed data from over 400,000 participants in the UK Biobank.

“Our study suggests that constipation, a common yet often overlooked health issue, may be a significant contributor to cardiovascular disease,” said Professor Marques.

“Traditional cardiovascular risk factors such as high blood pressure, obesity and smoking have long been recognised as key drivers of heart disease,” she said.

“However, these factors alone do not fully explain the occurrence of major cardiac events.”

“This study explored the potential role of constipation as an additional risk factor, revealing concerning results.”

The research team analysed data from 408,354 individuals, identifying 23,814 cases of constipation.

The findings showed that individuals suffering from constipation were more than twice as likely to suffer from a major cardiac event as those without constipation.

Moreover, the study highlighted a particularly concerning link between constipation and hypertension. 
Hypertensive individuals who also suffered from constipation were found to have a 34 per cent increased risk of subsequent cardiac events compared to those with hypertension alone.

“Our research suggests that constipation may exacerbate the cardiovascular risks associated with high blood pressure, further increasing the likelihood of heart attacks and strokes,” Professor Marques said.

In addition to these epidemiological findings, the study also explored the genetic links between constipation and cardiovascular disease. “Positive genetic correlations were identified between constipation and various forms of MACE, indicating that shared genetic factors may underlie both conditions. This discovery opens new avenues for research into the underlying mechanisms that connect gut health and heart health,” Dr Leticia Camargo Tavares, co-first author of the study, explained.

“The implications of this study are far-reaching,” Professor Marques said.

“With constipation affecting an estimated 14 per cent of the global population, particularly older adults and women, these findings suggest that a significant portion of the population may be at an increased risk of cardiovascular disease due to their bowel health,” she said.

The study authors emphasised the need for further research to explore the causal relationship between constipation and MACE and to identify the specific biological pathways involved. One of these mechanisms may be via a ‘leaky gut’. The team is recruiting participants to answer this question (www.marqueslab.com/gut).

This research challenges the traditional understanding of cardiovascular risk factors and underscores the importance of considering gut health in the prevention and management of heart disease. As the global burden of cardiovascular disease continues to rise, these findings could pave the way for new strategies in personalised medicine, helping to identify individuals at higher risk and potentially reducing the incidence of life-threatening cardiac events.

Media enquiries:
Silvia Dropulich
Marketing, Media & Communications Manager, Monash Science
T: +61 3 9902 4513 M: +61 435 138 743
Email: [email protected]

Hande Cater, Media and Communications Manager, Monash University
M: 0456 428 906
E: [email protected]

 

More from this category

  • Medical Health Aged Care
  • 08/12/2025
  • 10:11
BeOne Medicines Ltd.

Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies

Novel BCL2 inhibitor sonrotoclax monotherapy demonstrates deep and durable clinical responses in R/R MCL and R/R CLL Sonrotoclax in combination with BRUKINSA demonstrated rapid…

  • Contains:
  • Medical Health Aged Care
  • 08/12/2025
  • 09:40
Miltenyi Biomedicine

Miltenyi Biomedicine presents primary analysis of the pivotal DALY 2-EU trial for second-line relapsed/refractory large B-cell lymphoma at the 67th American Society of Hematology (ASH) Annual Meeting

DALY 2-EU results show zamtocabtagene autoleucel (zamto-cel) demonstrated clinically meaningful superiority over chemoimmunotherapy in patients with relapsed/refractory large B-cell lymphoma (r/r LBCL)1Zamto-cel was well-tolerated in the majority of patients. DALY 2-EU included a high-risk study population, characterized by older age and clinically high-risk disease featuresA 12-day manufacturing time resulted in a vein-to-vein time of 14-16 days, reducing the likelihood for bridging therapy.BERGISCH GLADBACH, Germany, Dec. 07, 2025 (GLOBE NEWSWIRE) -- Miltenyi Biomedicine today announced results from the pivotal DALY 2-EU trial evaluating the efficacy and safety of zamtocabtagene autoleucel (zamto-cel) compared with standard chemoimmunotherapy (R-GemOx or Pola-BR) in patients with…

  • Science
  • 08/12/2025
  • 09:30
Monash University

Monash researchers uncover ancient genetic switch that lets plants grow, adapt and survive

A team of scientists from Monash University has identified a single gene in a land plant that could help explain how plants first evolved the ability to grow continuously, a key trait that allowed them to colonise dry land and shape life on Earth. Published in Current Biology, the study focuses onMarchantia polymorpha, a liverwort whose ancestors diverged from flowering plants more than 400 million years ago. Despite its small size, this humble plant harbours a genetic mechanism that appears to have been critical for the early evolution of land plants. The gene, called MpARF2, acts as a master regulator…

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.